ABCL — AbCellera Biologics Share Price
Last trade - 00:00- $721.13m
- $95.52m
- $28.83m
- 54
- 26
- 48
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.68 | ||
| Price to Tang. Book | 0.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 25.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.52% | ||
| Return on Equity | -14.75% | ||
| Operating Margin | -1091.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 233.16 | 375.2 | 485.42 | 38.02 | 28.83 | 27.61 | 37.73 | 19.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +6.76 | +4.43 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.
Directors
- Carl L. Hansen CEO (46)
- Veronique Lecault CFD (36)
- Kevin Heyries CFD
- Andrew Booth CFO (47)
- Ester Falconer CTO (46)
- Tryn Stimart CCO (51)
- Neil Aubuchon OTH
- Neil Berkley OTH
- Michael Hayden IND (69)
- Andrew Lo IND
- John Montalbano IND (56)
- Peter Thiel IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 8th, 2012
- Public Since
- December 11th, 2020
- No. of Shareholders
- 79
- No. of Employees
- 596
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 297,987,669
- Address
- 150 W 4Th Avenue, VANCOUVER, V5Y 1G6
- Web
- https://www.abcellera.com/
- Phone
- +1 6045599005
- Auditors
- KPMG LLP
Latest News for ABCL
Upcoming Events for ABCL
Abcellera Biologics Inc at Bloom Burton & Co Healthcare Investor Conference
Q1 2025 Abcellera Biologics Inc Earnings Release
Q1 2025 Abcellera Biologics Inc Earnings Call
Abcellera Biologics Inc at Goldman Sachs Global Healthcare Conference
Abcellera Biologics Inc Annual Shareholders Meeting
Q2 2025 Abcellera Biologics Inc Earnings Release
Similar to ABCL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:02 UTC, shares in AbCellera Biologics are trading at $2.42. This share price information is delayed by 15 minutes.
Shares in AbCellera Biologics last closed at $2.42 and the price had moved by -38.27% over the past 365 days. In terms of relative price strength the AbCellera Biologics share price has underperformed the S&P500 Index by -41.95% over the past year.
The overall consensus recommendation for AbCellera Biologics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAbCellera Biologics does not currently pay a dividend.
AbCellera Biologics does not currently pay a dividend.
AbCellera Biologics does not currently pay a dividend.
To buy shares in AbCellera Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.42, shares in AbCellera Biologics had a market capitalisation of $721.13m.
Here are the trading details for AbCellera Biologics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABCL
Based on an overall assessment of its quality, value and momentum AbCellera Biologics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AbCellera Biologics is $12.00. That is 395.87% above the last closing price of $2.42.
Analysts covering AbCellera Biologics currently have a consensus Earnings Per Share (EPS) forecast of -$0.62 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AbCellera Biologics. Over the past six months, its share price has underperformed the S&P500 Index by -6.56%.
As of the last closing price of $2.42, shares in AbCellera Biologics were trading -12.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AbCellera Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AbCellera Biologics' management team is headed by:
- Carl L. Hansen - CEO
- Veronique Lecault - CFD
- Kevin Heyries - CFD
- Andrew Booth - CFO
- Ester Falconer - CTO
- Tryn Stimart - CCO
- Neil Aubuchon - OTH
- Neil Berkley - OTH
- Michael Hayden - IND
- Andrew Lo - IND
- John Montalbano - IND
- Peter Thiel - IND